Neurology in Biological Technology
Navigation Links
Neurology in Biological Technology
... disease at the 2009 American Academy of neurology meeting in Seattle, WA. The NuroPro tests help ... Marcopoulou, M.D., Assistant Professor of neurology at the University of Thessaly, Greece, gave a ... includes Stanley H. Appel, M.D. Chair of neurology at Methodist Neurological Research Institute in ...
... industry with specific expertise in building neurology assets for success. The two will serve in ... and chief medical officer at Somaxon, a neurology and psychiatry-focused specialty pharmaceutical ... corporate development at Jazz Pharmaceuticals, a neurology and psychiatry-focused specialty pharmaceutical ...
... Fahn, M.D., the H. Houston Merritt Professor of neurology and Director of the Center for Parkinson's ... is led by Lucien Cte, M.D., Professor of neurology at Columbia University, and Karen Marder, M.D., M.P.H., the Sally Kerlin Professor of neurology at Columbia University. "With a disease like ...
... data from this trial next year," said Dr. Mark Freedman, Professor of neurology at the University of Ottawa and Director of the MS Research Clinic at the ... with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to ...
... et al. Neurogastroenterol Motil 2004; 16: 383-394,5 (5) Gimbel JS et al. neurology 2003; 60: 927-934 (6) Watson CP et al. neurology 1998; 50 : 1837-1841 (7) Staahl C et al. Differential effect of opioids ...
... and the burden on caregivers," said study investigator, Daniel Murman, M.D., M.S., Associate Professor and Director, Memory Disorders and Behavior neurology Program with the Department of Neurological Sciences at the University of Nebraska Medical Center . "This information shows that not only are AD ...
... candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of neurology (AAN) conference. "In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic ...
... development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks ...
... and T cells. The results of phase II and long-term follow-up treatment of MS patients with dirucotide, published in 2006 in the European Journal of neurology (EJN), showed that dirucotide delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types ...
... at the University of California, San Diego . Prior to that, he held research positions at the Neuropsychology Laboratory at the Salk Institute, the neurology Department at the Medical School of the University of California at Irvine , and the Cognitive Psychophysiology Laboratory at the University ...
... of living with uncontrolled seizures," said lead study author Professor Peter Halasz, MD, PhD, National Institute of Psychiatry and Neurology, neurology Department, Budapest. "Vimpat(R) showed significant efficacy versus placebo in a challenging clinical trial patient population." In the study, ...
... needs worldwide. The company's major therapeutic areas of focus include hematology, oncology, infectious disease, obesity and metabolic disorders, neurology and psychiatry, pain and women's health. About Janssen Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., based in ...
... to seek stem cell treatments," said Dr. Olle Lindvall, co-chair of the ISSCR task force that developed the guidelines and professor in clinical neurology at the University of Lund. "Stem cell research holds tremendous promise for the development of novel therapies for many serious diseases. However, ...
... Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com . "Safe Harbor" Statement under the Private ...
... and easy access to daily online first research published across The Lancet journals (The Lancet, The Lancet Infectious Diseases, The Lancet neurology and The Lancet Oncology). - Free access to exclusive online-only editorial analysis of how the most important published research impacts ...
... The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients ...
... Faculty of Medicine, Department of Neurology and Neurosurgery, and Department of Medicine, McGill University, and member of the Attending Staff in neurology at Sir Mortimer B. Davis - Jewish General Hospital, in Montreal, Canada. "This proof-of-concept gives us great hope that biospectroscopy will offer a ...
... industry with specific expertise in building neurology assets for success. The two will serve in ... and chief medical officer at Somaxon, a neurology and psychiatry-focused specialty pharmaceutical ... corporate development at Jazz Pharmaceuticals, a neurology and psychiatry-focused specialty pharmaceutical ...
... Fahn, M.D., the H. Houston Merritt Professor of neurology and Director of the Center for Parkinson's ... is led by Lucien Cte, M.D., Professor of neurology at Columbia University, and Karen Marder, M.D., M.P.H., the Sally Kerlin Professor of neurology at Columbia University. "With a disease like ...
Avicena Appoints Dr. M. Flint Beal to Board of Directors
... professor and chairman of the department of neurology and neuroscience at the Weill Medical College at Cornell University, and director of neurology at New York Presbyterian Hospital. Prior to Cornell, Dr. Beal was the professor of neurology at the Harvard Medical School and chief of the ...NeurogesX Reports Second Quarter 2008 Results
... - Phase 1 clinical trial of NGX-1998 initiated - Journal neurology published positive Phase 3 data on NGX-4010 in HIV-DSP SAN MATEO, ... Phase 2 study in 2009. During the second quarter of 2008, the journal neurology published data from NeurogesX' Phase 3 pivotal trial (C107) in patients ...... data from this trial next year," said Dr. Mark Freedman, Professor of neurology at the University of Ottawa and Director of the MS Research Clinic at the ... with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to ...
Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
... it to market. Dr. Katz also served as Professor of Ophthalmology, neurology and Neurosurgery, and as the Chairman of the Department of Ophthalmology ... University of California at San Francisco after completing residencies in neurology at Harvard Medical School and in Ophthalmology at Tufts-New England ...Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
... led by Dr. Steven Hersch, were published in the January 24, 2006 issue of neurology and showed that HD-02 suppressed an oxidative damage marker, 8OH2DG, which ... General Hospital, were published in the January 24, 2006 issue of neurology and showed that HD-02 suppressed a Huntington's disease marker. Some ...Amarin Signs Agreement to Acquire Ester Neurosciences
... Adds Promising Phase II neurology Candidate $8.1 Million Financing in Connection With Acquisition ... advancing Ester's programs along with our existing development pipeline in neurology and cardiovascular disease." Eli Hazum, Chief Executive Officer of Ester ...Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
... residencies in pediatrics at New York University School of Medicine and in neurology at Harvard Medical School. Dr. Siffert was certified by the American Board of neurology and Psychiatry. He holds an M.D. degree from the University of Sao Paulo ...... et al. Neurogastroenterol Motil 2004; 16: 383-394,5 (5) Gimbel JS et al. neurology 2003; 60: 927-934 (6) Watson CP et al. neurology 1998; 50 : 1837-1841 (7) Staahl C et al. Differential effect of opioids ...
... and the burden on caregivers," said study investigator, Daniel Murman, M.D., M.S., Associate Professor and Director, Memory Disorders and Behavior neurology Program with the Department of Neurological Sciences at the University of Nebraska Medical Center . "This information shows that not only are AD ...
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
... stem cell-based screens and assays. Dr. Lennart Mucke is the director of the Gladstone Institute of Neurological Disease, and a professor of neurology and Neuroscience at UCSF. His research focuses on processes that result in memory loss and other major neurological deficits, with an emphasis on ...... candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of neurology (AAN) conference. "In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic ...
iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board
... iPS technology to the development of new therapeutics for unmet medical needs. We will look to Dr. Goodman's extensive knowledge and leadership in neurology to help advance our proprietary neurodegenerative programs in amyotrophic lateral sclerosis, spinal muscular atrophy and Parkinson's disease," said ...Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
... specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com . FORWARD-LOOKING STATEMENTS This press release ...NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
... and commercializing novel pain management therapies, announced today the presentation of two posters at the 61st Annual American Academy of neurology (AAN) meeting in Seattle, Washington. These posters, titled "Neurologic Safety of Treatment with NGX-4010, a High-Concentration Capsaicin Patch, in ...Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
... development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks ...Medivation Announces Upcoming Scientific Presentations at Medical Conferences
... MDV3100 on Sunday, April 26, at 4:00 p.m. Central Time (POD17. Prostate Cancer: Advanced Dimebon 61st American Academy of neurology (AAN) Annual Meeting, April 25 - May 2, Seattle Two poster presentations featuring Dimebon that will take place on: ...... development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks ...
Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
... Immunex Corporation from 1999 - 2001. In that capacity, he managed the discovery, development, manufacture and marketing for Immunex oncology and neurology products. Mr. Parker received his undergraduate degree in Biological Sciences from the University of Chicago , an MBA from the University of ...Alpine Biomed Opens New Manufacturing Facility to Support Demand for Specialty Diagnostic Devices
... devices in the industry." About Alpine Biomed Alpine Biomed is a global leader in specialty diagnostic devices for the gastroenterology and neurology clinical markets. The company produces diagnostic tools used for gastroesophageal reflux disease (GERD), commonly referred to as acid reflux disease, ...... and T cells. The results of phase II and long-term follow-up treatment of MS patients with dirucotide, published in 2006 in the European Journal of neurology (EJN), showed that dirucotide delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types ...
... at the University of California, San Diego . Prior to that, he held research positions at the Neuropsychology Laboratory at the Salk Institute, the neurology Department at the Medical School of the University of California at Irvine , and the Cognitive Psychophysiology Laboratory at the University ...
... of living with uncontrolled seizures," said lead study author Professor Peter Halasz, MD, PhD, National Institute of Psychiatry and Neurology, neurology Department, Budapest. "Vimpat(R) showed significant efficacy versus placebo in a challenging clinical trial patient population." In the study, ...
Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
... pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com . (Logo: ...Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
... is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com . "Safe Harbor" Statement under the Private Securities ...Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
... of Cincinnati , his M.D. from Vanderbilt University and his neurosurgical training at Baylor College of Medicine . Dr. Waltz also had training in neurology at The National Hospital for Neurological Diseases and in Neuropathology at Oxford University , both in the U.K. About Peregrine ...... needs worldwide. The company's major therapeutic areas of focus include hematology, oncology, infectious disease, obesity and metabolic disorders, neurology and psychiatry, pain and women's health. About Janssen Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., based in ...
Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
... pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com . About Dow Dow Pharmaceutical Sciences, ....... to seek stem cell treatments," said Dr. Olle Lindvall, co-chair of the ISSCR task force that developed the guidelines and professor in clinical neurology at the University of Lund. "Stem cell research holds tremendous promise for the development of novel therapies for many serious diseases. However, ...
Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
... 37 per cent. Out of the 260 cancer compounds in clinical development in Europe, Denmark accounts for 17 per cent of the European pipeline. neurology (15 per cent) and inflammation/autoimmune diseases (14 per cent) are the fields with second and third most Danish compounds in clinical trials. ...ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia
... About Avineuro Pharmaceuticals, Inc.: Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Founded in August 2008 and headquartered in San Diego, California, Avineuro is managed by seasoned professionals experienced in drug ...... Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com . "Safe Harbor" Statement under the Private ...
... and easy access to daily online first research published across The Lancet journals (The Lancet, The Lancet Infectious Diseases, The Lancet neurology and The Lancet Oncology). - Free access to exclusive online-only editorial analysis of how the most important published research impacts ...
Global Psychiatrists Unite to Improve Services in Mental Health
... Dr Wolfgang Fleischhacker, Medical University Innsbruck, Austria Dr Marcelo Cetkovich-Bakmas, the Department of Psychiatry, Institute of Cognitive neurology (INECO), and the Department of Psychiatry, Institute of Neurosciences, Favaloro Foundation, Buenos Aires, Argentina Dr Marc De Hert, University ...... The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients ...
Dr. Yong Shi awarded NSF grant
... on the project are Professor Sundeep Mangla (M. D., Director of Interventional Neuroradiology , Associate Professor of Radiology, Neurosurgery, and neurology ) and Professor Ming Zhang (M.D, Assistant Professor, Dept of Anesthesiology), both from SUNY Downstate Medical Center at Brooklyn, New York. ...... Faculty of Medicine, Department of Neurology and Neurosurgery, and Department of Medicine, McGill University, and member of the Attending Staff in neurology at Sir Mortimer B. Davis - Jewish General Hospital, in Montreal, Canada. "This proof-of-concept gives us great hope that biospectroscopy will offer a ...
BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
... The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients ...Other ContentsfilamentfilamentfilamentintermediateintermediateintermediateintermediateintermediateintermediateintermediateintermediateintermediateinsulininsulininsulininsulininsulininsulininsulininsulinspacespacespacespacespacespacespacespacespacespaceintermembraneintronintronintroninterphaseinterphasechannelchannelchannelchannelchannelchannelchannelchannelchannelOther Tags
(Date:11/9/2009)...dren with cancer, the hopeful news is that pediatr...es. Among the bad newstreatments that enable survi...with cancer who have reached puberty currently hav...re undergoing cancer treatment, they may have thei...er boys, however, do not produce sperm, although t...
(Date:11/9/2009)...lutionary biologists David Queller and Joan Strass...d low conflict between components, from the geneti...ity," whether that thing is an animal, a plant, a ...ntists use to describe an organism, such as indivi...y not be necessary to achieve organismality. What ...
(Date:11/9/2009)... butterfly wings has inspired a 3.2m, three-year r...n in the fields of security, energy and the enviro...technology company QinetiQ have just signed a coll...ed on groundbreaking physical sciences research. ... from the University of Exeter and QinetiQ will wo...
Breaking Biology News(10 mins):For young boys with cancer, testicular tissue banking may be option to preserve fertility 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 3What is the meaning of 'one'? 2What is the meaning of 'one'? 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 13886 1Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 13886 2Working Moms Vision Not Near Perfect 56357 1Working Moms Vision Not Near Perfect 56357 2Working Moms Vision Not Near Perfect 56357 3Update on velaglucerase alfa 13884 1Update on velaglucerase alfa 13884 2Update on velaglucerase alfa 13884 3(Date:11/9/2009)... Fast food chains are often b...y. A recent poll by Fitness.com.au however finds t...er the responsibility. , ...od chains, and video games were behind Australia&r... are more than just innocent bystanders. A recent ...
(Date:11/9/2009)... Course, to be Offered in Apr... Toolkit , Cambridge, MA ... Physicians for Human Rights (PHR) first inspected...nistan , he realized he would need a team of exper...enting the site properly was a key first step in s...
(Date:11/9/2009)..., The National Comprehensive Cancer Network (NCCN)... that details a draft paradigm for near-term compa...on existing data. The document introduces the NCCN...sus-based process that compares the risk-versus-be...n the NCCN Clinical Practice Guidelines in Oncolog...
(Date:11/9/2009)..., LEBANON, Tenn., Nov. 9 Health Co...nnounced it will host their inaugural Hospital O.R...2010 at the Marriott Renaissance Hotel in Nashvill...g more than 100 hospital operating room directors ...d health systems in the country. Some of the confi...
(Date:11/9/2009)..., CHICAGO, Nov. 9 Highlighting a c...utions with advanced entertainment and digital dis...ing its latest Long-Term Care and Hospital Grade L... Services for the Aging 2009 annual meeting and ex...ooth, the new line of "HealthView(TM)" Long-Term C...
Breaking Medicine News(10 mins):Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4Health News:Health Connect Partners Hosts Hospital O.R. & Surgery Center Conference 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5[1] Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids[2] Physicians for Human Rights Offers Training in Crime Scene Documentation[0] NCCN Posts Comparative Effectiveness White Paper for Public Comment[1] Health Connect Partners Hosts Hospital O.R. & Surgery Center Conference[0] LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs
HomogenousDataFiledatasheetQBTfluorometersScreenReadyMotilinRadioligandTracersCharacterizedTopCountlanthanidephosphorimeterSpex
Other Tagsbloody 2watch 2watch 3feeling 2correlate 2correlate 3cooling 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |